Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Partners Group Private Equity

    MCap

    EUR702m

    Last close

    EUR10.20

    ▲ 882.70 (8,569.90%)

    KALA BIO

    MCap

    USD7m

    Last close

    USD0.91

    ▲ 0.27 (42.63%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

BiomX – executive interview

BiomX – executive interview

BiomX (NYSE: PHGE) is a microbiome company developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectal cancer (CRC), as well as bacteria that affect the appearance of the skin. Phage is a form of virus which attacks only bacteria. BiomX discovers and validates proprietary bacterial targets and customizes its natural and engineered phage compositions against these targets.

In our Israel office, EdisonTV interviews BiomX chief executive officer, Jonathan Solomon, providing us with an introduction to the company and an update on its progress.

< Previous
Next >

You may also be interested in these:

Industrials

EYDAP – equity proposition

Investment Companies

Webinar: Budget breakdown with Gervais Williams - What does it really mean?